Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies

Hou, Yingying; Chen, Min; Bian, Yuan; Hu, Yuan; Chuan, Junlan; Zhong, Lei; Zhu, Yuxuan; Tong, Rongsheng

doi:10.1038/s41541-024-00874-4

Cited by 2 publications

(2 citation statements)

References 153 publications

(177 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Notably, we observed an increased activation of myeloid and granulocytic cells in elderly VI vs. V, which indicated an aggressive innate immune reaction to Shigella infection in elderly vaccinated mice. These findings in elderly vaccinated mice are consistent with observations in human infections like SARS-CoV-2 [ 38 , 44 ].…”

Section: Discussionsupporting

confidence: 91%

“…We found Ccl8 and Pigr were upregulated in both young and elderly mice following L-DBF/ME/BECC470 vaccination. Ccl8 is a key gene involved in recruiting immune cells to sites of infection [ 37 ], and Pigr is responsible for transporting immunoglobulins across epithelial barriers to defend against pathogens [ 38 ]. This shared response in both young and elderly mice highlights the capacity of L-DBF/ME/BECC470 to stimulate the mobilization of immune cells.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Vaccination with a Protective Ipa Protein-Containing Nanoemulsion Differentially Alters the Transcriptomic Profiles of Young and Elderly Mice following Shigella Infection

Lu,

Raju,

Howlader

et al. 2024

Vaccines

View full text Add to dashboard Cite

Shigella spp. are responsible for bacillary dysentery or shigellosis transmitted via the fecal–oral route, causing significant morbidity and mortality, especially among vulnerable populations. There are currently no licensed Shigella vaccines. Shigella spp. use a type III secretion system (T3SS) to invade host cells. We have shown that L-DBF, a recombinant fusion of the T3SS needle tip (IpaD) and translocator (IpaB) proteins with the LTA1 subunit of enterotoxigenic E. coli labile toxin, is broadly protective against Shigella spp. challenge in a mouse lethal pulmonary model. Here, we assessed the effect of LDBF, formulated with a unique TLR4 agonist called BECC470 in an oil-in-water emulsion (ME), on the murine immune response in a high-risk population (young and elderly) in response to Shigella challenge. Dual RNA Sequencing captured the transcriptome during Shigella infection in vaccinated and unvaccinated mice. Both age groups were protected by the L-DBF formulation, while younger vaccinated mice exhibited more adaptive immune response gene patterns. This preliminary study provides a step toward identifying the gene expression patterns and regulatory pathways responsible for a protective immune response against Shigella. Furthermore, this study provides a measure of the challenges that need to be addressed when immunizing an aging population.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Resultsmentioning

confidence: 99%

Vaccination with a Protective Ipa Protein-Containing Nanoemulsion Differentially Alters the Transcriptomic Profiles of Young and Elderly Mice following Shigella Infection

Lu,

Raju,

Howlader

et al. 2024

Vaccines

View full text Add to dashboard Cite

show abstract

The Protection Level of S-RBD SARS-CoV-2 Immunoglobulin G Antibodies Using the Chemiluminescent Immunoassay Compared to the Surrogate Virus Neutralization Test Method

Indrati,

Horian,

Dewi

et al. 2024

Diagnostics

View full text Add to dashboard Cite

COVID-19 infection in high-risk populations is fatal and has a poor prognosis, necessitating a test to determine the protectiveness of immune response. Antibody testing is necessary to determine the body’s immune response to COVID-19 infection and also vaccination strategies. Among the various methods available, the chemiluminescent immunoassay (CLIA) test is more widely used and accessible to determine antibody levels. This study aimed to determine the protection level of S-RBD SARS-CoV-2 IgG using CLIA compared to the Surrogate Virus Neutralization Test (SVNT). The population of this study comprised all healthcare professionals who experienced S-RBD SARS-CoV-2 IgG antibody level examinations. S-RBD SARS-CoV-2 IgG antibody levels were examined using CLIA and SVNT. The cut-off was determined using a receiver operating characteristic (ROC) curve, and area under the curve (AUC) measurements were evaluated. The result showed a strong positive correlation between S-RBD SARS-CoV-2 IgG CLIA and SVNT, with a value of r = 0.933 and p < 0.001. The value ≥ 37.29 BAU/mL was determined as the cut-off based on SVNT 30% inhibition level with sensitivity, specificity, and positive and negative predictive values of 96.5%, 90.9%, 96.5%, and 90.9%, respectively. A titer of antibodies greater than or equal to 37.29 BAU/mL with CLIA showed the presence of protective antibodies compared to SVNT.

show abstract

Insights into vaccines for elderly individuals: from the impacts of immunosenescence to delivery strategies

Cited by 2 publications

References 153 publications

Vaccination with a Protective Ipa Protein-Containing Nanoemulsion Differentially Alters the Transcriptomic Profiles of Young and Elderly Mice following Shigella Infection

Vaccination with a Protective Ipa Protein-Containing Nanoemulsion Differentially Alters the Transcriptomic Profiles of Young and Elderly Mice following Shigella Infection

The Protection Level of S-RBD SARS-CoV-2 Immunoglobulin G Antibodies Using the Chemiluminescent Immunoassay Compared to the Surrogate Virus Neutralization Test Method

Contact Info

Product

Resources

About